These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9224335)

  • 1. p53 protein and gene alterations in pathological stage C prostate carcinoma.
    Salem CE; Tomasic NA; Elmajian DA; Esrig D; Nichols PW; Taylor CR; Skinner DG; Roy-Burman P; Lieskovsky G; Cote RJ
    J Urol; 1997 Aug; 158(2):510-4. PubMed ID: 9224335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.
    Prendergast NJ; Atkins MR; Schatte EC; Paulson DF; Walther PJ
    J Urol; 1996 May; 155(5):1685-92. PubMed ID: 8627854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of p53 mutations with metastatic prostate cancer.
    Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
    Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens.
    Al-Maghrabi J; Vorobyova L; Chapman W; Jewett M; Zielenska M; Squire JA
    Mod Pathol; 2001 Dec; 14(12):1252-62. PubMed ID: 11743048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
    Tamboli P; Amin MB; Xu HJ; Linden MD
    Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of p53 are common in early stage prostate cancer.
    Downing SR; Russell PJ; Jackson P
    Can J Urol; 2003 Aug; 10(4):1924-33. PubMed ID: 14503938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different patterns of p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of microdissected specimens.
    Yasunaga Y; Shin M; Fujita MQ; Nonomura N; Miki T; Okuyama A; Aozasa K
    Lab Invest; 1998 Oct; 78(10):1275-9. PubMed ID: 9800953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 is mutated in a subset of advanced-stage prostate cancers.
    Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC
    Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: p53 protein and gene alterations in pathological stage C prostate carcinoma.
    Moul JW; Bauer JJ; Sesterhenn IA; Stackhouse GB; Srivastava S
    J Urol; 1998 May; 159(5):1648-9. PubMed ID: 9554382
    [No Abstract]   [Full Text] [Related]  

  • 14. Transgenic mouse with human mutant p53 expression in the prostate epithelium.
    Elgavish A; Wood PA; Pinkert CA; Eltoum IE; Cartee T; Wilbanks J; Mentor-Marcel R; Tian L; Scroggins SE
    Prostate; 2004 Sep; 61(1):26-34. PubMed ID: 15287091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An uncertain role for p53 gene alterations in human prostate cancers.
    Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB
    Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.
    Bauer JJ; Sesterhenn IA; Mostofi KF; McLeod DG; Srivastava S; Moul JW
    Clin Cancer Res; 1995 Nov; 1(11):1295-300. PubMed ID: 9815924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity.
    Grossfeld GD; Olumi AF; Connolly JA; Chew K; Gibney J; Bhargava V; Waldman FM; Carroll PR
    J Urol; 1998 May; 159(5):1437-43. PubMed ID: 9554329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations.
    Shibata MA; Ward JM; Devor DE; Liu ML; Green JE
    Cancer Res; 1996 Nov; 56(21):4894-903. PubMed ID: 8895741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
    Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
    Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.